Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Policy issues relating to Medicare coverage for prosthetic urological interventions, including H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients."
Policy issues relating to a proposed FDA regulation on generic drug labeling.
H.R. 6, the 21st Century Cures Act.
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection Act.
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection.
Duration: February 1, 2014
to
September 30, 2015
General Issues: Health Issues , Taxation/Internal Revenue Code
Spending: about $190,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Chris Jones
Chief of Staff/Rep. Mike Ferguson
Deputy Chief of Staff/Rep. David McIntosh
Communications Dir./House Govt. Reform and Oversight Subcmte
Press Secretary/Rep. John Myers
Adam Higgins
Legislative Assistant/Rep. Mike Ferguson
Adam Higgin
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2015
Ferguson Strategies, LLC terminated an engagement in which they represented Endo Pharmaceuticals Inc. on Oct. 19, 2015.
Original Filing: 300758307.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Policy issues relating to Medicare coverage for prosthetic urological interventions, including H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients."
Policy issues relating to a proposed FDA regulation on generic drug labeling.
H.R. 6, the 21st Century Cures Act.
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on July 17, 2015.
Original Filing: 300738683.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Policy issues relating to Medicare coverage for prosthetic urological interventions, including H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients."
Policy issues relating to a proposed FDA regulation on generic drug labeling.
H.R. 6, the 21st Century Cures Act.
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 160, the Protect Medical Innovation Act.
S. 149, the Medical Device Access and Innovation Protection.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300726354.xml
Lobbying Issues
H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients."
H.R. 2, the "Medicare Access and CHIP Reauthorization Act.
21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry.
Policy issues relating to a proposed FDA regulation on generic drug labeling.
Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 160, the Protect Medical Innovation Act.
S.1 49, the Medical Device Access and Innovation Protection.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300702999.xml
Lobbying Issues
Policy issues relating to a proposed FDA regulation on generic drug labeling.
Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2014
In Q3, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $30,000. The report was filed on Oct. 14, 2014.
Original Filing: 300676084.xml
Lobbying Issues
Policy issues relating to Public Law No. 113-54, the "Drug Quality and Security Act."
Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Policy issues relating to a proposed FDA regulation on generic drug labeling.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2014
Ferguson Strategies, LLC amended a lobbying report for representation of Endo Pharmaceuticals Inc. in Q22014 on Sept. 3, 2014.
Original Filing: 300672644.xml
Lobbying Issues
Policy issues relating to a proposed FDA regulation on generic drug labeling.
Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2014
In Q2, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $20,000. The report was filed on July 16, 2014.
Original Filing: 300657648.xml
Lobbying Issues
Policy issues relating to a proposed FDA regulation on generic drug labeling.
Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2014
In Q1, Ferguson Strategies, LLC lobbied for Endo Pharmaceuticals Inc. , earning $20,000. The report was filed on April 19, 2014.
Original Filing: 300642915.xml
Lobbying Issues
Policy issues relating to a proposed FDA regulation on generic drug labeling. Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
Ferguson Strategies, LLC filed a lobbying registration on Feb. 13, 2014 to represent Endo Pharmaceuticals Inc., effective Feb. 1, 2014.
Original Filing: 300630419.xml
Issue(s) they said they’d lobby about: Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program. Policy issues relating to prescription drug labeling. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate